PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at 2nd Annual H.C. Wainwright Psychedelics Conference
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will present at the Second Annual H.C. Wainwright Psychedelics Conference. The event is slated to be held virtually on Dec. 6, 2021. Tryp’s chairman and CEO Greg McKee will provide an overview of the business and its pipeline, including the upcoming phase 2a clinical trials in fibromyalgia, phantom limb pain, binge eating disorder and other indications. McKee's presentation will be available on-demand through the H.C. Wainwright conference portal beginning at 7:00 a.m. ET. on Monday, Dec.…